Dose-response screening and western blot analysis verified the sensitivity of the cell lines towards PIK-75, as well as the dual mTOR/PI3K-targeting dactolisib, thus permitting further pre-clinical studies on the PI3K/AKT/mTOR oncogenic pathway in metastatic cSCC. This evidence concerns the gene PIK3CA and skin squamous cell carcinoma.